Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Duloxetine (Primary)
Indications Diabetic neuropathies; Neuropathic pain
Focus Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

09 Oct 2008 Checked against the ClinicalTrials.gov record.
19 Aug 2008 Interim results presented at the 12th World Congress on Pain, according to a Boehringer Ingelheim media release.
20 Dec 2007 Status changed from in progress to completed.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight